Xintela AB is a biomedical company. It engages in the business of developing medical products in stem cell therapy and targeted cancer therapy based on the cell surface marker integrin a10ß1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The company was founded by Evy Lundgren-Åkerlund and Rickard Mosell in 2009 and is headquartered in Lund, Sweden.